| Ozbourn Chiropractic Clinic | |
|
101 Transcraft Dr Anna IL 62906-2114 | |
| (618) 833-2179 | |
| (618) 438-5119 |
| Full Name | Ozbourn Chiropractic Clinic |
|---|---|
| Speciality | Clinic/Center |
| Location | 101 Transcraft Dr, Anna, Illinois |
| Authorized Official Name and Position | Dennis Ray Mcguire (PRESIDENT) |
| Authorized Official Contact | 6184352500 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ozbourn Chiropractic Clinic 101 Transcraft Dr Anna IL 62906-2114 Ph: (618) 833-2179 | Ozbourn Chiropractic Clinic 101 Transcraft Dr Anna IL 62906-2114 Ph: (618) 833-2179 |
| NPI Number | 1811281728 |
|---|---|
| Provider Enumeration Date | 06/08/2011 |
| Last Update Date | 06/08/2011 |
| Medicare PECOS PAC ID | 9032381140 |
|---|---|
| Medicare Enrollment ID | O20111014000423 |
News Archive
Like many other conditions, obesity is caused by an interplay between genetic and environmental factors. While efforts to combat the obesity epidemic will need to include changes in diet and exercise, insights into the genes involved may also help with prevention and treatment.
NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
The bacterium that causes syphilis, Treponema pallidum, likely uses a single gene to escape the immune system, research from UW Medicine in Seattle suggests.
A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811281728 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Jason S Ozbourn |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1437458304 PECOS PAC ID: 9931371044 Enrollment ID: I20111014000438 |
News Archive
Like many other conditions, obesity is caused by an interplay between genetic and environmental factors. While efforts to combat the obesity epidemic will need to include changes in diet and exercise, insights into the genes involved may also help with prevention and treatment.
NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
The bacterium that causes syphilis, Treponema pallidum, likely uses a single gene to escape the immune system, research from UW Medicine in Seattle suggests.
A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.
› Verified 9 days ago
News Archive
Like many other conditions, obesity is caused by an interplay between genetic and environmental factors. While efforts to combat the obesity epidemic will need to include changes in diet and exercise, insights into the genes involved may also help with prevention and treatment.
NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
The bacterium that causes syphilis, Treponema pallidum, likely uses a single gene to escape the immune system, research from UW Medicine in Seattle suggests.
A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.
› Verified 9 days ago
Hunter Reach Family Medicine, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 98 Peach Ridge Road, Anna, IL 62906 Phone: 618-614-1400 Fax: 618-614-1401 | |
Anna Cc Sch Dist 37 Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 301 S Green St, Anna, IL 62906 Phone: 618-833-6812 Fax: 618-833-3205 | |
Deaconess Illinois Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 513 N Main St, Anna, IL 62906 Phone: 618-998-7177 Fax: 618-998-7742 | |
Deaconess Illinois Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 515 N Main St, Anna, IL 62906 Phone: 618-833-4511 Fax: 618-833-2414 | |
Anna Cc Sch Dist 37 Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 301 S Green St, Anna, IL 62906 Phone: 618-833-6812 Fax: 618-833-3205 | |
Union County Family Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 515 N Main St, Suite C, Anna, IL 62906 Phone: 618-833-2872 Fax: 618-833-2414 | |
Convenient Care Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 517 N Main St, Anna, IL 62906 Phone: 618-833-4511 Fax: 618-833-8481 |